Advertisement

Sanofi-aventis CEO Chris Viebacher outlined the research and development strategy that led to the purchase of Cambridge-based Genzyme Corp. for $20.1 billion and will lead the company to further expand its partnerships and acquisitions.

“My goal as CEO is never to inaugurate a new research and development center,” Viebacher said during an MIT Enterprise Forum event, at the start of his first full week as CEO of Genzyme, now a Sanofi subsidiary.

SOURCE

Advertisement
Advertisement